Identification of differentially expressed genes in pathways of cerebral neurotransmission of anovulatory mice
Received: January 18, 2017
Accepted: September 04, 2017
Published: September 27, 2017
Genet.Mol.Res. 16(3): gmr16039622
DOI: 10.4238/gmr16039622
Abstract
Polycystic ovary syndrome is the classic example of loss of functional cyclicity and anomalous feedback. In this case, the excessive extra-glandular production and conversion of androgens to estrogens are the pathophysiological basis of the chronic anovulation. The literature describes an experimental model of the polymicrocystic ovary in obese diabetic mice with insulin resistance. The fact that these animals exhibit obesity, insulin resistance, and infertility demonstrates their skill as an experimental model for polycystic ovary. A recent study using long protocol for up to 40 weeks showed that anovulatory and obese mice transplanted with adipose tissue from animals with normal weight have multiple changes in their phenotype. These changes include reduction of body weight, prevention of obesity, insulin level normalization, and insulin tolerance tests, preventing the elevation of steroids and especially the reversal of fertility restoration with anovulation. Considering that there are close relationships between the ovulation process and the central nervous system, we propose to evaluate the gene expression levels of 84 different genes involved in neurotransmission and insulin pathways in addition to examining the neurolipidosis differential murine brain before and after reversal of anovulation. The present study showed changes in gene expression of molecular markers in brain tissue of animals for brain neurotransmission pathways as well as pathways for insulin. GABAergic genes, muscarinic, serotonin receptors, receptor tyrosine kinase, and genes of interleukin 6 showed overexpression profile. There was also a change in the lipid content in anovulatory brain, obesity, and insulin resistant mice (Ob-/Ob-) compared with controls. The re-introduction of leptin in these animals appears to reverse, at least in part, this profile
Introduction
Polycystic ovary syndrome (PCOS) is one of the most frequent observed endocrinopathies of women during their reproductive age, and it is estimated to affect 6.8% of them (Diamanti- Kandarakis et al., 1999). Different from the previous hypothesis, PCOS seems now to be more related to insulin resistance rather than to the initially regarded as hyperandrogenism in reproductive age. Indeed, the insulin resistance and hyperinsulinemia participate in reproductive as well as metabolic disturbances associated with PCOS (Diamanti-Kandarakis, 2008). Implications may even extend beyond the reproductive axis, creating a need for a modified therapeutic management of affected women, especially from the cardiovascular point-of-view.
Another hallmark of the syndrome is a high GnRH pulse frequency resulting in elevated LH levels and LH/FSH ratio stimulating ovarian androgen production. It has been demonstrated that these women have decreased hypothalamic sensitivity to progesteronemediated feedback, in addition to reduced luteal phase progesterone production resulting from frequent anovulatory cycles. This effect is mediated by androgens and aggravated by insulin resistance (Blanksby and Mitchell, 2010).
In animal models, a similar reproductive endocrine phenotype occurs when the Leptin gene is knockdown. Despite the well-known fact that the central nervous system plays a major role in PCOS, very little is known about the specific molecular events that take place inside the brain during the anovulatory process and metabolic syndrome.
Therefore, in the present article, our aim was to analyze the expression of 84 genes involved in modulating the biological processes of neurotransmitter biosynthesis, uptake, transport, and signaling through brain neurotransmitter receptors of female obese, insulinresistant, non-ovulating, leptin-deficient (Ob/Ob) mice. Neurotransmission gene expression was further analyzed in the brain after the re-introduction of leptin in these animals.
Material and Methods
In vivo murine studies
Six-week-old female obese ob/ob mice together with their lean littermate controls were used. All procedures were approved by the Federal University of São Paulo Institutional Animal Care and Use Committee. Animals were housed with ad libitum access to food and water.
All animals were maintained in a temperature-controlled environment at ±24°C under a 12:12-h light-dark cycle and handled at least one time per week. Diet was a regular chow (F6 Rodent Diet; Harlan Teklad, Madison, WI, USA) comprised of 52% carbohydrate, 18% fat, and 31% protein by calorie or KD (F-3666; Bio-Serv, Frenchtown, NJ, USA) comprised of 0.4% carbohydrate, 95% fat, and 4.5% protein by calorie. Animal groups were divided as follows: 1- Control group (CG): Composed of 5 normal weight, 2 to 3 months of age B6.V-Lepob/J mice. After sacrifice brains were removed and kept in liquid nitrogen until use. 2- Obesity group (OG): Composed of 5 overweight, anovulatory, 2 to 3 months of age B6.V-Lepob/J mice. After sacrifice brains were removed and kept in liquid nitrogen until use. 3- Obesity group transplanted (OGT): Composed of 5 overweight, anovulatory, 2 to 3 months of age B6.V-Lepob/J mice that were recipient to fat transplantation from ovulating mice and sacrificed after 7 days of transplant. After sacrifice brains were removed and kept in liquid nitrogen until use.
Fat tissue transplant
Five female leptin-deficient (B6.V-Lepob/J, referred to as ob/ob) mice and their lean littermates were obtained from the animal facility of our University. A group of ob/ob mice received fat tissue transplantation as described by Gavrilova et al. (2000). Briefly, gonadal fat from wild-type littermates euthanized by cervical dislocation was placed in sterile PBS and cut into small pieces. The grafts were implanted subcutaneously through small incisions in the shaved skin of the back of recipient ob/ob mice anesthetized with isoflurane.
Approximately 1 g tissue was transplanted per mouse. Incisions were closed using wound clips and mice observed for wound closure. The second group of ob/ob mice was sham-operated. Mice were observed for 7 days after transplant, at which point they were sacrificed by cervical dislocation under isoflurane anesthesia.
RT profiler PCR-array mouse neurotransmitter receptors and regulators
The Mouse Neurotransmitter Receptors and Regulators RT2 ProfilerTM PCR Array, containing 84 genes involved in neurotransmission, was applied and run in triplicates together with five housekeeping genes (18srRNA, HPRT1, RPL13A, GAPD, and ACTB). Whole mouse brain was subjected to RNA extraction, cDNA synthesis, and PCR array as recommended by the manufacturer.
The amount of total RNA was quantified in ng/μL using the Nanodrop device. Gel electrophoresis of selected samples was performed on denaturating 2.0% agarose gel containing ethidium bromide and revealed the two rRNA bands corresponding to 28S and 18S. Sample purity was determined by calculating the 260/280 ratios and found within the 1.6 to 2.2 range in all samples.
The samples were stored at -80°C and cDNA was obtained by using the Reaction ReadyTM First-Strand cDNA Synthesis Kit (SuperArray), and the procedures were performed following the manufacturer’s instructions.
Negative control for genomic DNA and contaminating RNA were also conducted in each sample. Amplification, data acquisition, and the melting curve were carried out by iCycler iQ (Bio-Rad Laboratories, Hercules, CA, USA). The Ct and the melting curve of every gene were observed for every animal.
The threshold to determine the Ct value for each gene was automatically established by the iCycler iQ version 3 software that determined the SD of the points forming the baseline. Results are reported as Ct and normalized with the housekeeping gene 18SrRNA. The foldchange ratio for each gene was compared between the brain anovulatory groups and healthy mice counterparts. Analysis of variance followed by the Dunnett post hoc multiple comparison tests was used to compare the Ct results generated by the RT Profiler PCR Array between anovulatory groups against the control group. Genes are reported as differently expressed between groups when the fold-change was at least three-fold up-regulated or down-regulated, and the P value (analysis of variance and post-test) was lower than or equal to 0.05.
Neurotransmitter receptors analyzed
Acetylcholine Receptors: Anxa9, Chrm3.
Muscarinic Acetylcholine Receptors: Chrm1, Chrm2, Chrm3, Chrm4, Chrm5.
Adrenocorticotropin Receptors: Mc2r.
Bombesin Receptors: Brs3, Grpr.
Cholecystokinin Receptors: Cckar, Cckbr.
Dopamine Receptors: Drd1a, Drd2, Drd3, Drd4, Drd5.
GABA-A Receptors: Gabra1, Gabra2, Gabra3, Gabra4, Gabra5, Gabra6, Gabrb2, Gabrb3, Gabrd, Gabrg1, Gabrg2, Gabrp, Gabrq, Gabrr1, Gabrr2, Glra1, Glra2, Glra3, Glra4.
Gastrin Receptors: Cckar, Cckbr, Galr1, Galr2, Galr3.
Neuromedin U Receptors: Nmur1, Nmur2.
Neuropeptide Receptors: Npffr1 (Gpr147), Npffr2 (Gpr74), Ntsr1.
Neuropeptide Y Receptors: Gpr103, Prokr1 (Gpr73), Prokr2 (Gpr73l1), Gpr83, Npy1r, Npy2r, Npy5r, Npy6r, Pgr15l, Ppyr1, Prlhr (Gpr10).
Peptide YY Receptors: Npy1r, Npy2r, Npy5r, Npy6r, Ppyr1.
Somatostatin Receptors: Sstr1, Sstr2, Sstr3, Sstr4, Sstr5.
Tachykinin Receptors: Tacr1, Tacr2, Tacr3.
Other Neurotransmitter Receptors: Chrna1, Chrna2, Chrna3, Chrna4, Chrna5, Chrna6, Chrna7, Chrnb1, Chrnb2, Chrnb3, Chrnb4, Chrnd, Chrne, Chrng, Glrb, Htr3a.
Regulation of neurotransmitter levels
Neurotransmitter Biosynthesis: Chat, Gad1, Slc5a7
Neurotransmitter Catabolism: Ache, Comt, Maoa.
Immunohistochemistry
To further confirm our results and also identify the localization of protein expression in the brain, immunohistochemistry was also performed for the most up-regulated genes, Gabrb3 and Gabrg2.
Results
Among the 84 genes studied between the brain of normal and obese mice, we identified 34 as differentially expressed after statistical analysis. Of that, 13 were considered down-regulated and 21 up-regulated (Table 1). Remarkably, after only 7 days of the fat tissue transplant, only one gene, Tacr3, remained up-regulated in the brain of the transplanted group.
Functional gene groupings | Obese mice fold-change | P value | 7 days of transplant | P value |
---|---|---|---|---|
Neurotransmitter Receptors | ||||
Acetylcholine Receptors | ||||
Anxa9 | -4.11 | 0.020670 | -9.32 | 0.000062 |
Chrm3 | -1.79 | 0.974012 | -7.57 | 0.000000 |
Muscarinic Acetylcholine Receptors | ||||
Chrm1 | 48.84 | 0.091955 | -3.07 | 0.000211 |
Chrm2 | 2.66 | 0.150482 | -2.10 | 0.001728 |
Chrm3 | -1.79 | 0.974012 | -7.57 | 0.000000 |
Chrm4 | 1.69 | 0.214442 | -2.58 | 0.001921 |
Chrm5 | 1.08 | 0.370781 | -2.17 | 0.006942 |
Adrenocorticotropin Receptors | ||||
Mc2r | -3.34 | 0.068337 | -3.07 | 0.000145 |
Bombesin Receptors | ||||
Brs3 | -6.92 | 0.023793 | -3.07 | 0.016254 |
Grpr | -2.53 | 0.708941 | -2.50 | 0.000156 |
Cholecystokinin Receptors | ||||
Cckar | -4.56 | 0.051037 | -5.74 | 0.007709 |
Cckbr | -1.03 | 0.427239 | -4.66 | 0.003998 |
Dopamine Receptors | ||||
Drd1a | -1.31 | 0.688211 | -6.59 | 0.000385 |
Drd2 | -1.31 | 0.712160 | -5.17 | 0.002160 |
Drd3 | -1.18 | 0.575474 | -1.48 | 0.225068 |
Drd4 | -2.53 | 0.394967 | -10.34 | 0.000607 |
Drd5 | -4.11 | 0.116153 | -6.36 | 0.000010 |
GABA-A Receptors | ||||
Gabra1 | 58.08 | 0.079586 | -4.20 | 0.000085 |
Gabra2 | 3.05 | 0.142180 | -2.68 | 0.003229 |
Gabra3 | 17.27 | 0.102259 | 1.44 | 0.750036 |
Gabra4 | 20.53 | 0.121194 | -1.54 | 0.255686 |
Gabra5 | 8.06 | 0.100040 | -5.94 | 0.005289 |
Gabra6 | 5.13 | 0.120686 | -14.12 | 0.000000 |
Gabrb2 | 22.78 | 0.095446 | -5.54 | 0.003224 |
Gabrb3 | 232.32 | 0.070995 | -2.97 | 0.000424 |
Gabrd | 2.16 | 0.170917 | -5.74 | 0.000006 |
Gabrg1 | 3.76 | 0.267210 | 1.26 | 0.403649 |
Gabrg2 | 164.28 | 0.071247 | -1.09 | 0.443929 |
Gabrp | 1.16 | 0.333973 | -3.41 | 0.000438 |
Gabrq | -1.79 | 0.967364 | -3.18 | 0.005660 |
Gabrr1 | -2.62 | 0.444059 | -2.58 | 0.100276 |
Gabrr2 | -1.56 | 0.651516 | -2.97 | 0.006893 |
Glra1 | -2.53 | 0.479330 | -2.50 | 0.117328 |
Glra2 | -2.13 | 0.602807 | -2.87 | 0.006055 |
Glra3 | 3.89 | 0.115340 | -1.09 | 0.700959 |
Glra4 | -2.62 | 0.665324 | -3.41 | 0.022184 |
Gastrin Receptors | ||||
Cckar | -4.56 | 0.051037 | -5.74 | 0.007709 |
Cckbr | -1.03 | 0.427239 | -4.66 | 0.003998 |
Galr1 | -4.72 | 0.016241 | -5.74 | 0.000000 |
Galr2 | -2.81 | 0.304981 | -2.87 | 0.148685 |
Galr3 | -2.71 | 0.260494 | -1.13 | 0.301424 |
Neuromedin U Receptors | ||||
Nmur1 | -1.36 | 0.487064 | -3.41 | 0.005531 |
Nmur2 | -1.79 | 0.953509 | -3.07 | 0.000493 |
Neuropeptide Receptors | ||||
Npffr1 (Gpr147) | -2.13 | 0.840610 | -8.69 | 0.000004 |
Npffr2 (Gpr74) | 1.47 | 0.230477 | -1.96 | 0.002482 |
Ntsr1 | 1.16 | 0.292900 | -2.03 | 0.019582 |
Neuropetide Y Receptors | ||||
Qrfpr | 4.32 | 0.067335 | -1.16 | 0.357521 |
Prokr1 (Gpr73) | -3.84 | 0.170310 | -2.41 | 0.095515 |
Prokr2 (Gpr7311) | -1.99 | 0.833335 | -1.09 | 0.468912 |
Gpr83 | 1.88 | 0.190744 | -7.06 | 0.000002 |
Npy1r | 1.64 | 0.239341 | -1.83 | 0.046601 |
Npy2r | 1.53 | 0.251263 | -1.54 | 0.054869 |
Npy5r | 10.27 | 0.097446 | -2.03 | 0.000747 |
Npy6r | -3.23 | 0.276981 | -4.66 | 0.015249 |
Pgr15l | 1.58 | 0.225764 | 1.21 | 0.114330 |
Ppyr1 | -2.20 | 0.609688 | -3.41 | 0.001583 |
Prlhr (Gpr10) | -1.79 | 0.945939 | -3.18 | 0.004313 |
Peptide YY Receptors | ||||
Npy1r | 1.64 | 0.239341 | -1.83 | 0.046601 |
Npy2r | 1.53 | 0.251263 | -1.54 | 0.054869 |
Npy5r | 10.27 | 0.097446 | -2.03 | 0.000747 |
Npy6r | -3.23 | 0.276981 | -4.66 | 0.015249 |
Ppyr1 | -2.20 | 0.609688 | -3.41 | 0.001583 |
Somatostatin Receptors | ||||
Sstr1 | -1.31 | 0.888664 | -1.09 | 0.499841 |
Sstr2 | 11.39 | 0.120448 | -1.83 | 0.182661 |
Sstr3 | -3.01 | 0.629782 | -5.35 | 0.000059 |
Sstr4 | 2.08 | 0.889827 | -1.43 | 0.214445 |
Sstr5 | 2.16 | 0.174080 | -1.16 | 0.357521 |
Tachykinin Receptors | ||||
Tacr1 | -2.36 | 0.844945 | -2.41 | 0.002405 |
Tacr2 | -6.23 | 0.010367 | -11.47 | 0.001098 |
Tacr3 | 14.03 | 0.109652 | 4.53 | 0.026174 |
Other Neurotransmitter Receptors | ||||
Chrna1 | -6.92 | 0.001124 | -7.06 | 0.000001 |
Chrna2 | 2.01 | 0.436780 | -2.33 | 0.170204 |
Chrna3 | -1.27 | 0.579056 | -9.65 | 0.000013 |
Chrna4 | 2.23 | 0.182199 | -4.50 | 0.022366 |
Chrna5 | -4.89 | 0.066526 | -2.41 | 0.078253 |
Chrna6 | -2.36 | 0.552564 | -2.97 | 0.000157 |
Chrna7 | -3.23 | 0.328895 | -3.18 | 0.047374 |
Chrnb1 | -3.58 | 0.162537 | -1.96 | 0.113367 |
Chrnb2 | 8.34 | 0.173478 | 1.26 | 0.326259 |
Chrnb3 | -2.81 | 0.310689 | -1.89 | 0.101501 |
Chrnb4 | -3.97 | 0.123375 | -7.84 | 0.000201 |
Chrnd | 4.96 | 0.124909 | -1.25 | 0.166996 |
Chrne | -15.35 | 0.015633 | -10.70 | 0.013186 |
Chrng | -1.99 | 0.823609 | -2.25 | 0.028641 |
Glrb | 94.35 | 0.066486 | 1.49 | 0.538925 |
Htr3a | -4.26 | 0.175870 | -2.87 | 0.089983 |
Regulation of Neurotransmitter | ||||
Levels Neurotransmitter Biosynthesis | ||||
Chat | -1.14 | 0.656465 | -2.87 | 0.040200 |
Gad1 | 27.10 | 0.086453 | -2.33 | 0.093293 |
Slc5a7 | 4.63 | 0.167870 | 1.26 | 0.493606 |
Neurotransmitter Catabolism | ||||
Ache | 2.08 | 0.181419 | -2.97 | 0.000575 |
Comt | -1.40 | 0.979578 | -6.36 | 0.000836 |
Maoa | 3.51 | 0.108982 | -2.68 | 0.002493 |
Table 1: Gene expression level in of the brain analysis of anovulatory mice.
A gene expression analysis was performed for all the genes described before and after transplantation, it was possible to notice that the great majority of the genes presented were hyperexpressed (Figure 1) at the moment before transplantation and after 7 days of the Transplantation, it was possible to identify a notable reversal of this characteristic (Figure 2).
Immunohistochemistry analysis
The results obtained in the immunohistochemical tests confirmed the molecular findings by using antibodies specific for the differentially expressed genes found in brain tissue of mice (Figures 3 and 4); it is possible to verify the presence of specific large-scale brain tissue antibodies.
Discussion
In the present article, we were able to identify aberrant expression of genes in the brain of female obese, insulin-resistant, non-ovulating mice. Indeed, after analyzing 84 genes involved in modulating biological processes such as neurotransmitter biosynthesis, uptake, transport, and signaling we identified, after a triplicate real-time PCR confirmation, a total of 34 genes whose expression were found altered in the brain from anovulatory animals.
Among these genes, the GABA-A receptors were the most abundant up-regulated category responding for 32.2% (11 of 34 genes) of all differentially expressed genes. The second more abundantly affected category of neurotransmitter receptors, in anovulatory brains, was the Cholinergic Receptors Nicotinic (CHRN) accounting for 20.5% (7 of 34 genes) of all abnormally expressed genes. The third more commonly misbalanced group of genes was the one involved in coding the Neuropeptide Y Receptors responding for 11.7% (4 of 34 genes) of all differentially expressed genes. The other 12 misbalanced genes were scattered in other classes displayed in Table 1.
It is well known that the feedback regulation of GnRH neurons by steroid hormones is critical to normal reproductive function and occurs in part through altered GABAergic drive to these cells (Qublan and Malkawi, 2005; Zafar, 2005; Rouzi et al., 2006; Freret et al., 2006; Costello et al., 2007a,b). Altered sensitivity to steroid feedback is associated with forms of hypothalamic infertility such as the common reproductive disorder PCOS, a leading cause of infertility in women.
Indeed, in the present study, we were able to show that in our model of anovulation, obesity and insulin resistance, the lack of leptin was followed by a remarkable up-regulation of GABA-A mRNA receptors that was completely normalized after only 7 days of leptin introduction.
This finding suggests that the GABAergic system may play a role in forms of hypothalamic infertility; however, there is some controversy on whether the GABAergic activity, a known inhibitory pathway, can inhibit GnRH neurons.
GABA inhibits most mature neurons, but this is controversial for GnRH neurons. In fact, GnRH neurons maintain elevated chloride (Chehab et al., 1996), as do other neurons derived from olfactory placode (Mounzih et al., 1997), and may thus be excited by GABA-A receptor activation. Studies using functional approaches to examine GnRH neurons differ as to whether GABA excites or inhibits these neurons (Chehab et al., 1996; Mounzih et al., 1997; Farooqi et al., 2002; Oral et al., 2002), but direct correlations between reduced fertility and reduced GABAergic drive support the former (Zhang et al., 1994; Schubring et al., 1997). Regardless of the response of GnRH neurons to GABAAR activation, GABAARs clearly play a role in fertility regulation.
The different actions of acetylcholine (ACh) are mediated by activation of nicotinic (ionotropic) and muscarinic (metabotropic) classes of receptors. Nicotinic receptors (nAChRs) are ligand-gated receptor channels that are cation-specific but do not distinguish readily among cations (Edman and MacDonald, 1978). Both classes of cholinergic receptors are expressed throughout the brain and are abundant in the hypothalamus, where monoaminergic neurons that terminate on GnRH and other peptidergic neurons are located (Goldzieherand Green, 1962). The GnRH neurons of the hypothalamus are innervated by noradrenergic neurons located in the hindbrain, and catecholamines have been implicated in the regulation of GnRH release. In contrast, there is less evidence for a role of cholinergic innervation in the control of GnRH secretion.
About the Authors
Corresponding Author
M.A. Azevedo Jr.
Laboratório de Ginecologia Molecular, Universidade Federal de São Paulo, São Paulo, SP, Brasil
- Email:
- marcosazevedojr@gmail.com
I.D.C.G. Silva
Laboratório de Ginecologia Molecular, Universidade Federal de São Paulo, São Paulo, SP, Brasil
- Email:
- Ismael.dale@gmail.com
References
- Blanksby SJ and Mitchell TW (2010). Advances in mass spectrometry for lipidomics. Annu. Rev. Anal. Chem. (Palo Alto, Calif.) 3: 433-465.https://doi.org/10.1146/annurev.anchem.111808.073705
- Chehab FF, Lim ME and Lu R (1996). Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat. Genet. 12: 318-320. https://doi.org/10.1038/ng0396-318
- Costello MF, Shrestha B, Eden J, Johnson NP, et al. (2007a). Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum. Reprod. 22: 1200-1209. https://doi.org/10.1093/humrep/dem005
- Costello M, Shrestha B, Eden J, Sjoblom P, et al. (2007b). Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. 24: CD005552.
- Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, et al. (1999). A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84: 4006-4011. https://doi. org/10.1210/jcem.84.11.6148
- Diamanti-Kandarakis E (2008). Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev. Mol. Med. 10: e3. https://doi.org/10.1017/S1462399408000598
- Edman CD and MacDonald PC (1978). Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. Am. J. Obstet. Gynecol. 130: 456-461. https://doi.org/10.1016/0002-9378(78)90288-0
- Farooqi IS, Matarese G, Lord GM, Keogh JM, et al. (2002). Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110: 1093-1103. https://doi.org/10.1172/JCI0215693
- Freret S, Grimard B, Ponter AA, Joly C, et al. (2006). Reduction of body-weight gain enhances in vitro embryo production in overfed superovulated dairy heifers. Reproduction 131: 783-794. https://doi.org/10.1530/rep.1.00689
- Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, et al. (2000). Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105: 271-278. https://doi.org/10.1172/JCI7901
- Goldzieher JW and Green JA (1962). The polycystic ovary. I. Clinical and histologic features. J. Clin. Endocrinol. Metab. 22: 325-338. https://doi.org/10.1210/jcem-22-3-325
- Mounzih K, Lu R and Chehab FF (1997). Leptin treatment rescues the sterility of genetically obese ob/ob males. Endocrinology 138: 1190-1193.https://doi.org/10.1210/endo.138.3.5024
- Oral EA, Simha V, Ruiz E, Andewelt A, et al. (2002). Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346: 570-578. https://doi.org/10.1056/NEJMoa012437
- Qublan HS and Malkawi HY (2005). Metformin in the treatment of clomiphene citrate-resistant women with high BMI and primary infertility: clinical results and reproductive outcome. J. Obstet. Gynaecol. 25: 55-59. https://doi. org/10.1080/01443610400025382
- Rouzi AA, Ardawi MSM and Path FRC (2006). A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril. 85: 428-435. https://doi.org/10.1016/j.fertnstert.2005.07.1312
- Schubring C, Kiess W, Englaro P, Rascher W, et al. (1997). Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight. J. Clin. Endocrinol. Metab. 82: 1480-1483. https:// doi.org/10.1210/jcem.82.5.3935
- Zafar S (2005). Role of metformin in correcting hyperinsulinemia, menstrual irregularity and anovulation in polycystic ovary syndrome. J. Ayub Med. Coll. Abbottabad 17: 54-56.
- Zhang Y, Proenca R, Maffei M, Barone M, et al. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432. https://doi.org/10.1038/372425a0
Keywords:
Download:
Full PDF- Share This